Hansa Biopharma AB (OSTO:HNSA) Cyclically Adjusted PB Ratio: (As of Sep. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:HNSA Hansa Biopharma AB OSTO:HNSA
35 GF Score
Price kr36.20
GF Value kr22.13
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Hansa Biopharma AB Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Hansa Biopharma AB  (OSTO:HNSA) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Hansa Biopharma AB Cyclically Adjusted PB Ratio Related Terms


Hansa Biopharma AB Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Hansa Biopharma AB's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hansa Biopharma AB Cyclically Adjusted PB Ratio Chart

Hansa Biopharma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.10 3.31 1.75 2.81 2.64

Hansa Biopharma AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.16 3.37 3.00 2.84 3.22

OSTO:HNSA vs VRTX, REGN, MRNA: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Hansa Biopharma AB's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hansa Biopharma AB Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hansa Biopharma AB's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Hansa Biopharma AB's Cyclically Adjusted PB Ratio falls into.


OSTO:HNSA
35GF Score
Hansa Biopharma AB OSTO:HNSA
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hansa Biopharma AB Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Hansa Biopharma AB's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Hansa Biopharma AB's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-5.216/134.6100*134.6100
=-5.216

Current CPI (Jun. 2026) = 134.6100.

Hansa Biopharma AB Quarterly Data

Book Value per Share CPI Adj_Book
201609 4.283 101.138 5.701
201612 8.093 102.022 10.678
201703 6.848 102.022 9.035
201706 5.665 102.752 7.421
201709 4.789 103.279 6.242
201712 16.681 103.793 21.634
201803 15.624 103.962 20.230
201806 14.257 104.875 18.299
201809 13.277 105.679 16.912
201812 21.518 105.912 27.349
201903 20.863 105.886 26.523
201906 18.873 106.742 23.800
201909 16.692 107.214 20.957
201912 14.061 107.766 17.564
202003 11.841 106.563 14.958
202006 9.446 107.498 11.828
202009 30.089 107.635 37.630
202012 27.930 108.296 34.717
202103 25.854 108.360 32.117
202106 23.188 108.928 28.655
202109 20.227 110.338 24.676
202112 17.034 112.486 20.384
202203 14.300 114.825 16.764
202206 10.810 118.384 12.292
202209 7.734 122.296 8.513
202212 11.496 126.365 12.246
202303 7.907 127.042 8.378
202306 3.474 129.407 3.614
202309 -1.186 130.224 -1.226
202312 -3.187 131.912 -3.252
202403 -7.105 132.205 -7.234
202406 -3.226 132.716 -3.272
202409 -4.718 132.304 -4.800
202412 -8.698 132.987 -8.804
202503 -9.224 132.825 -9.348
202506 -5.438 133.699 -5.475
202509 -6.615 133.480 -6.671
202512 -0.892 133.380 -0.900
202603 -2.760 133.550 -2.782
202606 -5.216 134.610 -5.216

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Hansa Biopharma AB (OSTO:HNSA) Overvalued in 2026?

Based on GuruFocus' analysis, Hansa Biopharma AB stock appears to be overvalued. The current stock price of kr36.20 is trading 63.6% above its estimated GF Value™ of kr22.13. GuruFocus considers Hansa Biopharma AB to be Significantly Overvalued.

Key valuation signals for OSTO:HNSA:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: kr22.13 vs. price of kr36.20 (63.6% above fair value)
  • GF Score™: 35/100 with 5 warning signs

No single metric tells the full story. See the OSTO:HNSA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Hansa Biopharma AB Business Description

Address Scheelevagen 22, Lund, SWE, 223 63
Hansa Biopharma AB is a commercial-stage biopharmaceutical company pioneering the development and commercialization of life-saving and life-altering therapies for patients with rare immunological conditions. It has developed a proprietary, first-in-class antibody-cleaving enzyme technology platform designed to eliminate pathogenic IgG antibodies. This differentiated platform supports a broad pipeline with potential applications across Transplantation, Autoimmune diseases, and Gene Therapy-areas characterized by unmet medical need. Hansa's first-generation IgG-cleaving enzyme, imlifidase, is designed to inactivate all four IgG subclasses (IgG1, IgG2, IgG3, and IgG4) in both the intravascular and extravascular compartments following a single intravenous administration.
35GF Score

Get the complete analysis for OSTO:HNSA

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr36.20
Price
kr22.13
GF Value